Interview with Virax MD Rob Crombie. Well presented and a good overview of what the company is about.
From 4:20 -
"Why do you say the Aktivate acquisition is largely de-risked?"
"These are clinical products so we are not going through the research process...we've fast forwarded that process into the clinics so we're buying those programs...not only that but these drugs are being administered to people as we speak...also these programs are funded by government grants"
From 11:30 -
"The only company that I know that has a comparable number of clinical trials running at once is Mesoblast, and it is has a market cap of $1.3 billion dollars"
Interesting times ahead.
VHL Price at posting:
0.9¢ Sentiment: Buy Disclosure: Held
